Welcome > Support > Reference Treatises  
 
 
E
 
Read
Writer panagene     (Date : 2010-10-19 10:32:51)
Subject [Scientific publications] [Panagene publication] PNA-Based Antisense Oligonucleotides for MicroRNAs Inhibition in the Absence of a Transfection Reagent.
Content

Oligonucleotides. 2010 Oct 14. [Epub ahead of print]

PNA-Based Antisense Oligonucleotides for MicroRNAs Inhibition in the Absence of a Transfection Reagent.

Oh SY, Ju Y, Kim S, Park H.

Panagene, Inc. , Daejeon, Korea.

Abstract

MicroRNAs (miRNAs) are noncoding RNAs approximately 22 nucleotides in length that play a major role in the regulation of important biological processes, including cellular development, differentiation, and apoptosis. Antisense oligonucleotides against miRNAs are useful tools for studying the biological mechanisms and therapeutic targets of miRNAs. Various antisense oligonucleotides chemistries, including peptide nucleic acids (PNAs), have been developed to enhance nuclease-resistance and affinity and specificity for miRNA targets. PNAs have a greater specificity and affinity for DNA and RNA than do natural nucleic acids, and they are resistant to nucleases—an essential property of an miRNA inhibitor that will be exposed to cellular nucleases. However, the main limiting factor in the use of PNAs is their reduced penetration into cells. Recently, several cell-penetrating peptides (CPPs) have been investigated as a means to overcome the limited penetration of PNAs. Here, we evaluated the ability of 11 CPPs to transport PNAs inside cells in the absence of transfection reagents and then investigated the ability of these CPPs to inhibit miRNAs. Of the 11 CPPs tested, Tat-modified-conjugated PNA showed the most effective penetration into cells in the absence of transfection reagents and most effectively inhibited miRNAs. Our data demonstrate that Tat-modified-conjugated CPP is the most suitable for supporting PNA-mediated miRNA inhibition.

PMID: 20946011 [PubMed - as supplied by publisher]

Link to - http://www.ncbi.nlm.nih.gov/pubmed/20946011


 

 No   Subject Writer File Count
   47           [Scientific publications] [2016]Comparison of EGFR .. Panagene 54599
   46           [Scientific publications] [2015]IDH Mutation Analys.. Panagene 32433
   45           [Scientific publications] [2015]Low frequency of KR.. Panagene 46143
   44           [Scientific publications] [2015]Simultaneous genoty.. Panagene 25466
   43           [Scientific publications] [2014]Simultaneous diagno.. Panagene 32138
   42           [Scientific publications] [2014]KRAS Mutation Detec.. Panagene 32914
   41           [Scientific publications] [2013]Detection of EGFR m.. Panagene 23816
   40           [Scientific publications] [2013]Detection and compa.. Panagene 24774
   39           [Scientific publications] [2013]Detection of BRAF V.. Panagene 28269
   38           [Scientific publications] [2013]Comparison of Direc.. Panagene 28273
   37           [Scientific publications] [PNAClamp]Detection of EG.. Panagene 31353
   36           [Scientific publications] [Clamp]Rapid and Sensitiv.. panagene 24007
   35           [Scientific publications] [PNA microarray] Developm.. Panagene 23858
   34           [Scientific publications] [PANArray¢â] JHDM3A module.. Panagene 28055
   33           [Scientific publications] [PNA Chip vs DNA Chip cli.. Panagene 23852
   32           [Scientific publications] [Panagene publication] PN.. Panagene 23867
¢º           [Scientific publications] [Panagene publication] PN.. panagene 29070
   30           [Scientific publications] [Panagene publication] Pe.. panagene 28951
   29           [Scientific publications] [Panagene publication] Hi.. panagene 32861
   28           [Scientific publications] [PNA]Membrane-based hybri.. Panagene 28671
 

< 1 2 3 >